Cheap Deals, Dead Companies

Inflation has been persistent. That was true before the Iran war started in late February, and it’s aggressively more true now. CPI hit 3.3% year-over-year in March, up from 2.4% the month before. Brent crude has swung from $72 pre-war to nearly $120 at its peak, settling around $94 with ceasefire talks producing nothing definitive. The Strait of Hormuz is still functionally closed. The Fed held rates at 3.5-3.75% for the second straight meeting, and some FOMC members are openly discussing the possibility of hikes. Markets are pricing a 98% chance of no cut at the April meeting.

Any hope for a quick return to low interest rates is probably out the window.

The standard VC take on this is about valuation compression. Entry prices come down. Deals get cheaper. And that’s true as far as it goes, which isn’t very far. The more interesting question is what happens underneath the headline numbers… because inflation doesn’t just reprice companies. It reprices the viability of entire business models.

The Mechanism

Most early-stage companies, especially in sectors like biotech, computational chemistry, and deep tech, operate with long pre-revenue runways. They need 18 to 24 months of funded development before they have anything resembling proof of concept. In a low-rate environment, that’s fine. Capital is cheap, fund managers have deployment pressure, and the cost of running experiments is relatively stable.

In an inflationary environment, three things change simultaneously.

First, the cost of running those experiments goes up. Lab supplies, specialized equipment, energy costs, and clinical trial logistics all get more expensive. A burn rate that looked reasonable in a 2% inflation world isn’t the same burn rate in a 3.3% world, and that gap compounds over 18 months.

Second, the capital available to fund those experiments shrinks. LPs get more conservative. Fund managers with deployment timelines start filtering harder. Series A and B rounds take longer to close, and the bar for what constitutes “enough traction” rises. This is the part that doesn’t show up in valuation headlines… it’s not that the deals are more expensive, it’s that fewer deals get done at all.

Third, the opportunity cost of capital increases. When treasuries yield 4%+ with zero execution risk, the hurdle rate for a pre-revenue biotech company goes up mechanically. The risk premium investors need to justify a five-year illiquid bet gets wider, not because the company got worse but because the alternative got better.

A Filter, Not a Discount

The result is a funding environment that selectively punishes the most capital-intensive, longest-duration companies. Precisely the ones working on problems that matter. And that’s a shame worth acknowledging. But acknowledging it doesn’t change the math.

This isn’t a valuation story. It’s a selection filter. And the distinction matters because the two lead to completely different decision frameworks. If you think inflation is a valuation story, you look for cheaper entry points on the same types of companies. If you think it’s a selection filter, you rethink which companies can survive the journey to proof in the current cost environment.

The companies that look relatively more attractive are the ones with short paths to revenue, or at least to meaningful validation milestones. Low burn rates. Business models where the next twelve months of progress don’t depend on an expensive, energy-intensive, supply-chain-dependent validation process. It’s not that those companies are inherently better businesses. It’s that they’re better bets in this specific environment because their survival doesn’t depend on assumptions about cheap capital that stopped being true years ago.

The companies that get riskier are the ones that need 18+ months of funded runway in a tightening environment. The capital they need to get from hypothesis to proof is getting more expensive to raise and more expensive to deploy. Both sides of the equation move against them.

But here’s where the filter gets interesting. The same environment that makes capital-intensive companies harder to fund makes the infrastructure that supports them more valuable. Tools that compress clinical trial timelines. Platforms that decentralize trial infrastructure. Software that makes expensive science cheaper and faster. If the cost of getting to proof is the binding constraint, then anything that structurally lowers that cost has more demand, more pricing power, and a clearer path to revenue… exactly the characteristics the filter selects for. That’s not a workaround. That’s where durable businesses get built during cycles like this.

What This Means for Founders

For founders, the practical implication is straightforward. The path to your next round just got harder, and the difficulty didn’t come from your product, your team, or your market. It came from the macro environment making your timeline more expensive. The founders who internalize this and find ways to compress their validation cycles… whether through better tooling, leaner trial designs, or infrastructure that didn’t exist two years ago… are the ones who’ll still be fundraising from a position of strength. The ones who budget for 2021 timelines in a 2026 rate environment are going to run out of runway before they run out of ideas.

That’s not a macro trade. It’s a deal selection filter. And it’s the one nobody’s putting in their deck.